L3VLUP
ProSign in

LEGN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LEGNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LEGN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterLEGNVRTX
Q3 20202 holders, $116m31 holders, $21.9bn
Q4 20203 holders, $123m30 holders, $18.4bn
Q1 20214 holders, $170m31 holders, $15.4bn
Q2 20214 holders, $178m30 holders, $12.7bn
Q3 20215 holders, $387m35 holders, $10.1bn
Q4 20216 holders, $401m28 holders, $12.4bn
Q1 20227 holders, $338m23 holders, $16.1bn
Q2 20229 holders, $993m25 holders, $18.1bn
Q3 20228 holders, $847m22 holders, $18.4bn
Q4 20229 holders, $1.1bn28 holders, $18.4bn
Q1 202310 holders, $1.2bn26 holders, $21.4bn
Q2 202311 holders, $2.5bn27 holders, $24.7bn
Q3 202312 holders, $2.4bn33 holders, $24.3bn
Q4 202311 holders, $2.1bn32 holders, $28.6bn
Q1 202410 holders, $2.1bn31 holders, $29.8bn
Q2 20248 holders, $1.6bn29 holders, $33.4bn
Q3 20249 holders, $1.8bn27 holders, $33.5bn
Q4 202410 holders, $523m26 holders, $28.5bn
Q1 20258 holders, $916m21 holders, $35.4bn
Q2 20256 holders, $1.1bn21 holders, $32.3bn
Q3 20255 holders, $1.1bn22 holders, $25.9bn
Q4 20256 holders, $679m26 holders, $31.8bn
Q1 20264 holders, $155m25 holders, $31.8bn
Q2 20265 holders, $1.0bn26 holders, $34.6bn
LEGN

Legend Biotech Corp

Holders
9
Reported value
$1.8bn
Buyers
7
Sellers
2

Breadth +5 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 29 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only LEGN (2)

Balyasny Asset Management LLC, Bridgewater Associates LP

Only VRTX (20)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →